Stock Analysis
Thermo Fisher Scientific, Inc.TMO
P/E 36.62×· 5Y range 22.71–39.15×· top 12% of history
Sector: Healthcare · Industry: Diagnostics & Research
AnalystsStrong Buy36 analystsP/E 36.6× sits at the 88th percentile of its 5.086926762491444-year history.
Cash covers 26% of debt · FY 2025.
PMP Verdict
Mixed fundamentals, expensive valuation
Strengths
- Quality85
- Financial Health65
Risks
- Valuation22
- Growth31
Mixed fundamentals at a demanding price.
Bull Case
- ✓Altman Z 4.3 — safe-zone balance sheet
What's happening with TMO
Profile
Strong earnings quality; valuation and growth lag behind.
How is each axis scored?
- Valuation22/100 · Weak
- P/E vs own history (88th pct)0/25
- FCF yield (2.9%)5/25
- P/S (5.5x)12/25
- EV/EBIT (34.9x)5/25
- Growth31/100 · Weak
- Revenue CAGR (3.2%)6/25
- Net income CAGR (-3.5%)0/25
- EPS CAGR 5Y (-2.3%)0/25
- Fwd implied growth (49.2%)25/25
- Profitability57/100 · Moderate
- ROIC (7.8%)5/25
- ROE (13.0%)12/25
- Net margin (15.0%)20/25
- Operating margin (17.6%)20/25
- Financial Health65/100 · Moderate
- Altman Z (4.28)25/25
- Current ratio (1.89)18/25
- Interest coverage (4.6x)10/25
- Net cash / debt (D/A 27%)12/25
- Quality85/100 · Strong
- Piotroski F (5/9)15/25
- Beneish M (-2.31)20/25
- FCF conversion (105%)25/25
- Margin stability (σ 4.3%)25/25
- Moat70/100 · Moderate
- ROIC >12% years (1/10 yrs)0/25
- Median gross margin (43.3%)20/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 10.6%)25/25
Risk Flags
- ⚠P/E 36.6× at top 12% of 5-year history
About Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. Show more
The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Headquarters: WALTHAM, MA · Employees: 125,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
22EP/E (TTM)36.6xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 22.7x–39.1x · 88th pct
P/FCF34.8xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield2.9%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 2.3%–4.5% · 25th pct
P/S (TTM)5.51xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 3.4x–6.8x · 86th pct
EV/EBIT34.9xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 21.9x–37.8x · 82nd pct
EV/Sales6.3xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E24.6xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio4.78xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio3.87D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield0.26%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio9.5%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
57CROIC7.8%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE13.0%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA6.3%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin15.0%A
Grade A: HighNet Income / Revenue
Operating Margin17.6%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin40.8%C
Grade C: AverageGross Profit / Revenue
FCF Margin15.8%A
Grade A: HighFCF / Revenue
True FCF Margin15.1%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
31DRevenue CAGR3.2%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-3.5%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-2.3%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth49.2%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-6.9%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income4.6%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue0.7%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
65BAltman Z-Score4.28A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.89xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio1.18xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage4.6xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment4.0yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT3.6xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity0.74xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.26xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
85APiotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.31A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion105.0%A
Grade A: StrongFCF / Net Income
Margin Stability4.3%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue3.7%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.42xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Keith R. Alexandra Filed | Keith R. Alexandra | Grant / award | +46 | |
WEISLER DION J Filed | WEISLER DION J | Grant / award | +56 | |
Lynch Karen S Filed | Lynch Karen S | Grant / award | +46 | |
SPERLING SCOTT M Filed | SPERLING SCOTT M | Grant / award | +63 | |
JOHNSON JENNIFER M Filed | JOHNSON JENNIFER M | Grant / award | +46 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Pettiti Gianluca Filed | Pettiti Gianluca | Option exercise | -3733 | |
Pettiti Gianluca Filed | Pettiti Gianluca | SellOpen market sale | -3733 | |
Pettiti Gianluca Filed | Pettiti Gianluca | Option exercise | +3.7K |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
70B+ROIC >12% Years1/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)43.3%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor10.6%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$18.84
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$10.94
Cash & short-term investments per share (Finnhub)
Book Value / Share$141.77
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$39.38B
Total debt obligations (short + long term)
Cash & Equiv.$10.11B
Cash and short-term investments
Net Debt$29.28B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$53.41B
Shareholders' equity (book value)
Asset / Liability1.94xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$255.31B
Current Market Capitalization
Beta0.86B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Thermo Fisher Scientific, Inc. (TMO)
TMO is down 0.93% at the last close. Piotroski F-Score of 5/9 indicates mixed fundamentals for Thermo Fisher Scientific, Inc.. Altman Z-Score of 4.28 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.31 suggests a low likelihood of earnings manipulation.
- Thermo Fisher Scientific, Inc. converts about 16% of revenue into free cash flow — strong cash generation.
- Takes ~4.0 years to repay net debt from free cash flow.
- At a valuation score of 22/100, TMO trades at a premium to its historical multiples (P/E 36.6).
See how TMO ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all TMO moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 698.91 | +3.82% | 2.32 |
| Oct 15 | After-hours | 700.00 | +3.98% | 2.42 |
| Oct 6 | Regular | 657.53 | -2.84% | -2.17 |
| Oct 6 | After-hours | 659.00 | -2.62% | -2.03 |
| Oct 5 | After-hours | 678.56 | +3.63% | 2.06 |
Frequently Asked Questions about TMO
What is the current Thermo Fisher Scientific, Inc. (TMO) stock price?
TMO is trading at $690.00 at the last market close, down 0.93% on the session. PreMarketPrice tracks TMO pre-market, intraday and after-hours prices.
Is TMO stock a buy right now?
PreMarketPrice's quantitative model rates Thermo Fisher Scientific, Inc.'s financial health at 65/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is TMO stock overvalued?
Thermo Fisher Scientific, Inc. trades at a trailing P/E of 36.6 and our valuation score rates it 22/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Thermo Fisher Scientific, Inc. report earnings?
No confirmed earnings date is currently scheduled for TMO. The Earnings section lists recent reports and updates as dates are announced.
What sector does Thermo Fisher Scientific, Inc. operate in?
Thermo Fisher Scientific, Inc. operates in the Healthcare sector, within the Diagnostics & Research industry. The Related Stocks section lists sector peers for comparison.
What does Thermo Fisher Scientific, Inc. do?
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents.
About Thermo Fisher Scientific, Inc. (TMO) Stock
Thermo Fisher Scientific, Inc. (TMO) is a US-listed stock operating in the Healthcare sector, specifically the Diagnostics & Research industry. As of the latest update, Thermo Fisher Scientific, Inc. is trading at $690.00, down 0.93% on the day with a market capitalization of $255.3 billion. The financial health score for TMO is 65/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for TMO stock.
TMO Stock Analysis & Key Metrics
On PreMarketPrice, you can track Thermo Fisher Scientific, Inc. (TMO) across multiple dimensions:
- Pre-market price & movement: Real-time TMO stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for TMO with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Thermo Fisher Scientific, Inc. across multiple reporting periods.
- Financial health score: A composite score of 65/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for TMO.
- Sector peers: Compare TMO against 6 other healthcare stocks on key financial metrics.
Is TMO a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Thermo Fisher Scientific, Inc. (TMO) as an investment. The financial health score of 65/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Thermo Fisher Scientific, Inc. (TMO) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.